Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04082260 (ClinicalTrials.gov)	January 2017	28/8/2019	Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response	Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response	Multiple Sclerosis	Drug: Alemtuzumab Injection [Lemtrada]	University Hospital Muenster	NULL	Recruiting	18 Years	N/A	All	150		Germany
2	NCT04633967 (ClinicalTrials.gov)	May 15, 2016	26/10/2020	Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.	Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.	Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis	Drug: Alemtuzumab Injection	Maritime Neurology	NULL	Active, not recruiting	18 Years	65 Years	All	30		Canada